Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H29FN4O |
| Molecular Weight | 468.5662 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCNCCc1cccc(c1)Nc2ncc3C[C@]([H])(c4ccccc4-c3n2)c5ccccc5F
InChI
InChIKey=KPJDVVCDVBFRMU-AREMUKBSSA-N
InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
| Molecular Formula | C29H29FN4O |
| Molecular Weight | 468.5662 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment:: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28161661 | https://www.ncbi.nlm.nih.gov/pubmed/28240679 | https://clinicaltrials.gov/ct2/show/NCT01752920
Curator's Comment:: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28161661 | https://www.ncbi.nlm.nih.gov/pubmed/28240679 | https://clinicaltrials.gov/ct2/show/NCT01752920
Derazantinib (ARQ 087) is an investigational, oral, multi-kinase inhibitor designed to preferentially inhibit the FGFR family of kinases with demonstrated activity in FGFR2 genetic alterations, including fusions. In human cancers, FGFRs have been found to be dysregulated by multiple mechanisms, including aberrant expression, mutations, chromosomal rearrangements, and amplifications. FGFR dysregulation has been identified as a driver in a number of cancers, including iCCA, cholangiocarcinoma, bladder, endometrial, breast, gastric, lung and ovarian. Current scientific literature suggests FGFR alterations exist in anywhere from 5% to 40% of these cancers. Derazantinib is a potent FGFR inhibitor that shows strong anti-proliferative activity in cell lines harboring FGFR2 alterations. In clinical testing, the molecule has demonstrated activity in cancerous tumors harboring FGFR2 fusions in iCCA and bladder cancers.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4142 |
1.8 nM [IC50] | ||
Target ID: CHEMBL3650 |
4.5 nM [IC50] | ||
Target ID: CHEMBL2742 |
4.5 nM [IC50] | ||
Target ID: CHEMBL3973 |
34.0 nM [IC50] | ||
Target ID: CHEMBL2041 |
3.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
ARQ-087 orally at dose levels specified for their respective dose cohorts on a 28-day schedule. Dosing will begin at 25 mg every other day (QOD) and will escalate until the maximum tolerated dose (MTD)
Route of Administration:
Oral
NCI-H716 and SNU-16 cells were plated and incubated at 37°C overnight and subsequently treated with 0.1 μM or 1 μM of ARQ 087 for 24 or 72 hours. The cells were fixed and stained with Cycletest Plus Reagent kit (BD Biosciences, Franklin Lakes, NJ) according to the manufacturer’s instructions, and cell cycle profiles were analyzed using a FACS Calibur flow cytometer
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 09:31:10 UTC 2021
by
admin
on
Sat Jun 26 09:31:10 UTC 2021
|
| Record UNII |
N9B0H171MJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Sat Jun 26 09:31:10 UTC 2021 , Edited by admin on Sat Jun 26 09:31:10 UTC 2021
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Jun 26 09:31:10 UTC 2021 , Edited by admin on Sat Jun 26 09:31:10 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL3545421
Created by
admin on Sat Jun 26 09:31:10 UTC 2021 , Edited by admin on Sat Jun 26 09:31:10 UTC 2021
|
PRIMARY | |||
|
1814961-15-3
Created by
admin on Sat Jun 26 09:31:10 UTC 2021 , Edited by admin on Sat Jun 26 09:31:10 UTC 2021
|
NO STRUCTURE GIVEN | |||
|
C104267
Created by
admin on Sat Jun 26 09:31:10 UTC 2021 , Edited by admin on Sat Jun 26 09:31:10 UTC 2021
|
PRIMARY | |||
|
10488
Created by
admin on Sat Jun 26 09:31:10 UTC 2021 , Edited by admin on Sat Jun 26 09:31:10 UTC 2021
|
PRIMARY | |||
|
46834118
Created by
admin on Sat Jun 26 09:31:10 UTC 2021 , Edited by admin on Sat Jun 26 09:31:10 UTC 2021
|
PRIMARY | |||
|
1234356-69-4
Created by
admin on Sat Jun 26 09:31:10 UTC 2021 , Edited by admin on Sat Jun 26 09:31:10 UTC 2021
|
PRIMARY | |||
|
DB14889
Created by
admin on Sat Jun 26 09:31:10 UTC 2021 , Edited by admin on Sat Jun 26 09:31:10 UTC 2021
|
PRIMARY | |||
|
N9B0H171MJ
Created by
admin on Sat Jun 26 09:31:10 UTC 2021 , Edited by admin on Sat Jun 26 09:31:10 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
